Prudential Financial’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Prudential Financial’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400	Closed	-$2.69K	–	2780
2023 Q4	$2.69K	Buy	+400	New	+$3.52K	﹤0.01%	2643
2023 Q1	–	Sell	-6,680	Closed	-$236K	–	2687
2022 Q4	$236K	Buy	6,680 +87	+1%	+$10.5K	﹤0.01%	2349
2022 Q3	$1.49M	Buy	6,593 +4,548	+222%	+$1.12M	﹤0.01%	1521
2022 Q2	$387K	Buy	+2,045	New	+$412K	﹤0.01%	2231
2020 Q4	–	Sell	-534	Closed	-$130K	–	2514
2020 Q3	$130K	Buy	+534	New	+$166K	﹤0.01%	2344
2020 Q2	–	Sell	-387	Closed	-$79K	–	2481
2020 Q1	$79K	Buy	+387	New	+$123K	﹤0.01%	2283

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AWP

Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Prudential Financial's EIGR Position: Q1 2024 in Review

Prudential Financial sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 400 shares — an estimated $2.69K sold.

Prudential Financial first reported a position in EIGR in Q1 2020 and held it in 6 quarters. The position peaked at $1.49M in Q3 2022. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

Prudential Financial reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Prudential Financial sold 400 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $2.69K.
Prudential Financial first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2020 and held it in 6 quarters.
Prudential Financial's Eiger BioPharmaceuticals, Inc. position peaked at $1.49M in Q3 2022.
24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Prudential Financial's 13F filing for Q1 2024, filed 14 May 2024.